


# Stabilis



## Dactinomycin



### Noms commerciaux

Cosmegen	Argentine, Australie, Autriche, Canada, Etats Unis d'Amérique, Finlande, France, Grèce, Iran, Italie, Malaisie, Mexique, Norvège, Nouvelle Zélande, Suède, Suisse
Cosmegen Lyovac	Grande Bretagne, Irlande, Roumanie
Dacilon	Chili, Inde, Pérou
Dacmozen	Inde
Dactino	Inde
Dactinomicina	Chili, Colombie, Equateur, Pérou
Dactinomycin	Nouvelle Zélande
Lyovac Cosmegen	Allemagne, Belgique, Luxembourg, Pays bas



### Stabilité des solutions

Icon 1	Icon 2	Icon 3	Icon 4	Icon 5	Icon 6	Icon 7	Icon 8	Icon 9
		10 µg/ml	20-25°C	?	10			4153
		10 µg/ml	20-25°C	?	10			4153
		9.8 µg/ml	25°C		24			1178
PVC		10 µg/ml	20-25°C	?	10			4153
PVC		10 µg/ml	20-25°C	?	10			4153
PVC		9.8 µg/ml	25°C		24			1178






































### Facteur influençant la stabilité

				729
				857
				1322
	Eau ppi +bactériostatique			4153



## Compatibilités

				
		Dactinomycin : 10 µg/ml Allopurinol sodium : 3 mg/ml		307
		Dactinomycin : 10 µg/ml Amifostine : 10 mg/ml		3
		Dactinomycin : 10 µg/ml Aztreonam : 40 mg/ml		99
		Dactinomycin : 10 µg/ml Etoposide phosphate : 5 mg/ml		1410
		Dactinomycin : 10 µg/ml Filgrastim : 30 µg/ml		244
		Dactinomycin : 10 µg/ml Fludarabine phosphate : 1 mg/ml		492
		Dactinomycin : 10 µg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Dactinomycin : 10 µg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Dactinomycin : 10 µg/ml Melphalan : 0.1 mg/ml		169
		Dactinomycin : 10 µg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Dactinomycin : 10 µg/ml Sargramostim : 10 µg/ml		335
		Dactinomycin : 10 µg/ml Teniposide : 0.1 mg/ml		905
		Dactinomycin : 10 µg/ml Thiotepa : 1 mg/ml		249
		Dactinomycin : 10 µg/ml Vinorelbine tartrate : 1 mg/ml		84
		Dactinomycin		4153



## Voie d'administration



## Bibliographie








































	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.

84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
729	Revue	Rusmin S, Welton S, DeLuca P, DeLuca PP. Effect of inline filtration on the potency of drugs administered intravenously. Am J Hosp Pharm 1977 ; 34: 1071-1074.
857	Revue	Kanke M, Eubanks JL, DeLuca PP. Binding of selected drugs to a "treated" inline filter. Am J Hosp Pharm 1983 ; 40: 1323-1328.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1178	Revue	Benvenuto JA, Anderson RW, Kerkof K, Smith RG, Loo TL. Stability and compatibility of antitumor agents in glass and plastic containers. Am J Hosp Pharm 1981 ; 38: 1914-1918.
1322	Revue	Ennis CE, Merritt RJ, Neff DN. In vitro study of inline filtration of medications commonly administered to pediatric cancer patients. JPEN 1983 ; 7: 156-158.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.

1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
4153	Laboratoire	Dactinomycin (Cosmegen Lyovac®) - Summary of Product Characteristics Orphan Europe (UF) Limited 2014



# Dictionnaire

 Anticancéreux	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 Eau pour préparation injectable	 Non précisée
 Heure	 NaCl 0,9% ou glucose 5%
 Glucose 5%	 A l'abri de la lumière
 Polyvinyl chlorure	 Facteur influençant la stabilité
 Filtration	 Provoque
 Adsorption	 Diminution de la concentration
 Solvant	 Précipitation
 Compatibilités	 Molécule
 Compatible	 Chlorure de sodium 0,9%
 Précipitation immédiate	 Incompatible
 Eau ppi + bactériostatique	 Voie d'administration
 Intraveineuse	 Bibliographie
 Dictionnaire	